VEGFA and renal cell carcinoma: This independent review supported the PFS benefits of lenvatinib plus everolimus in comparison to everolimus alone for patients with metastatic RCC whose disease progressed after one previous VEGF-targeted treatment (Motzer, Hutson, Ren, Dutcus, & Larkin, 2016).